Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




Implementing Core Clinical Trial Technologies



By Bill Byrom

February 16, 2010 | Expert Commentary | In the clinical space today, more technology solutions are being used, and investigational sites often employ multiple solutions within a single study to perform their responsibilities. Solutions include clinical trials management systems (CTMS), electronic data capture (EDC) systems, electronic patient reported outcomes (ePRO) solutions, randomization and trial supply management (RTSM) solutions (typically deployed using IVR/IWR technology), medical imaging technologies, central ECG management and reporting solutions, adverse event and safety systems to name but a few.

Common to every clinical trial are the requirements to project manage and track the study; collect and clean CRF data recorded by the investigator; and manage the logistics of the study including the medication supply chain and the randomization process.

Many biopharmaceutical companies have invested significantly in these technologies and have adapted their processes and procedures to benefit from their use. Most large and mid-sized companies performing a number of clinical trials per year have purchased and licensed a commercial CTMS application. Some smaller organizations manage the same meta data and processes using spreadsheets and databases and while this can be successful for single studies, it is challenging when managing data across a portfolio of trials.

Some biopharmaceutical companies have determined that all phase 2 and 3 trials should employ EDC, and have geared up data management and monitoring resources to adapt to and apply the new electronic processes. In addition to reducing data management costs, EDC is associated with improving data quality, in particular speeding the data cleaning process, and has been reported to result in lower monitoring costs. Furthermore, the benefits in simplifying logistics and saving medication when using RTSM systems have been realized by many biopharmaceutical companies. Consequently, like EDC adoption, some sponsors choose to employ RTSM by default in all phase 2-3 studies.

Other clinical trial technologies, with the exception of safety systems, are used by individual trials when required and so we might consider the combination of CTMS, EDC and RTSM as foundational and required by every clinical trial, from which additional technologies may be required on a per-study basis.

Integration of Core Clinical Trial Technology Solutions
The challenge now becomes how CTMS, EDC and RTSM can be used in combination optimally so that users are not faced with duplication of data and activities, and workflows are not burdened with unnecessary keying of data between systems. Additionally, how can other technologies be hooked into these systems when they are needed by a study? 

Although each has unique areas of focus and application, there is overlap between the data and functionality contained within CTMS, EDC and RTSM solutions. This overlap can lead to increased burden in their application. For example, one of the key functions of a CTMS is to provide up-to-date information on study progress including patient recruitment, data management and source data verification (SDV). Senior management rely upon these data being accurately recorded in the CTMS, and as a consequence CRAs are often required to re-key data into the CTMS based upon the information contained within RTSM and EDC reports.

In addition, site users may receive dispensing information from an RTSM system and be required to enter it into the eCRF within the EDC application. Users may make mistakes in entering duplicate information leading to the requirement to reconcile data between databases, or may simply not perform the activity as it appears redundant to them although valuable to another user of the system. Figure 2 depicts the typical touch points between CTMS, EDC and RTSM systems.

Integrating the data between these systems has enormous benefits to the different user types involved in the operation of a clinical trial. Ensuring the CTMS contains accurate study progress data leverages the use of that system as the key management information system within the Sponsor. Key study progress data, if up to date, can also trigger timely site payments.

Providing integration between EDC and RTSM makes working with both technologies more efficient for study site users and monitors in eliminating duplication of activities, data and associated reconciliation, and in ensuring that the optimal value is obtained from each technology investment. Integrating site address and user details contained in a CTMS with the other technology solutions that require that data removes the needs for CRAs and study managers to create and maintain accurate duplicate lists of this information.

Simple data integration brings significant benefits to the users of these core technologies and leverages the value of each

Bill Byrom is Senior Director of Product Strategy, Perceptive Informatics, Nottingham, UK. 

Click here to log in.

1 Comments

  • Avatar

    Why should a sponsor look beyond ePRO?
    It is a known fact that it take huge amount of capital, usually in billions of dollars to conduct and finally launch a dug into the market. It is also known that there are several studies that are either terminated or stopped half way due to several reasons technical and non-technical associated with it resulting in wastage of time and money both. Patient related data capture during a clinical trial plays an important role in the making of a drug. Through out the different phases of clinical trials information from patients are taken for efficacy, BA, BE measurements and make a considerable part of the trials or study. A lot of sponsors have been using ePRO to collect patient reported outcome, still makes only 30-40 % of studies being conducted using EDC and further less using ePRO.
    It is time that sponsors look at more cost effective ways to gather PRO from subjects under trials and keep abreast with the pace of developing technologies. The next big wave in capturing PRO for clinical trials is the use of mobile phones and I am sure there are many a company that are working on it. Mobile phones are going to be the next computers that would enable users to manage all their communication and information transfer over mobile phones.
    What can a sponsor look at from a mobile phone based PRO?
    Well there are quite a few things for a Sponsor or for that matter a CRO to be looking at, when it comes to mobile based PRO system.
    Faster
    Compliant
    Cost effective
    Patient safety
    Logistically simpler
    Less erroneous data
    Data integrity and security
    New and improved features
    A information management system
    Check out more on www.padisys.com. For any queries or information kindly call up
    +18184531805 for US and +91 9948220071 for India.

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .